Trial Profile

Ramelteon And Suvorexant Efficacy For Prevention Of Delirium In Real World Patients With Delirium Risk Factor

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramelteon (Primary) ; Suvorexant (Primary)
Indications Delirium
Focus Therapeutic Use

Most Recent Events

26 Dec 2019 New trial record
17 Dec 2019 Primary endpoint (Incidence of delirium) has been met as per results published in the Journal of Clinical Psychiatry.
17 Dec 2019 Results, assessing efficacy of Ramelteon and Suvorexant for prevention of delirium in real world patients with delirium risk factor, published in the Journal of Clinical Psychiatry

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com